Document is current
Any future updates will be listed below
-
Authors
Okada, Takashi
Ida, Hiroyuki
Yamashita, Kouji
Saito, Kazuhiko
-
Funding
Funding for this research was provided by:
Takeda Pharmaceutical Company
Shionogi
- License Information
-
More Information
Article History
Received: 6 August 2025
Accepted: 1 December 2025
First Online: 12 March 2026
Declarations
:
: Takashi Okada has received consultancy fees from Otsuka Pharmaceutical Co. Ltd and lecture fees from EA Pharma Co. Ltd, Janssen Pharmaceutical K.K., Lundbeck Japan K.K., Meiji Seika Pharma Co. Ltd, Merck Sharp & Dohme K.K., Nobelpharma Co. Ltd, Otsuka Pharmaceutical Co. Ltd, Shionogi & Co. Ltd., Sumitomo Pharma Co. Ltd, Takeda Pharmaceutical Co. Ltd, Viatris Pharmaceuticals Japan G.K., and Yoshitomi Pharmaceutical Industries Ltd. Hiroyuki Ida is an employee of Takeda Pharmaceutical Co. Ltd. Kouji Yamashita is an employee of Takeda Pharmaceutical Co. Ltd and owns Takeda stock. Kazuhiko Saito has received speaker fees from Shionogi & Co. Ltd and Takeda Pharmaceutical Co. Ltd.
: Institutional Review Board and Ethics Committee approvals were not required for this post-marketing surveillance study according to the GPSP Ordinance. This study was conducted in accordance with the Declaration of Helsinki and in compliance with the Japanese Ministerial Ordinance on GPSP. Copyright licenses for the Clinical Global Impression–Improvement (CGI-I) scale and the ADHD Rating Scale IV (ADHD-RS-IV) were obtained prior to their use in this study. Patients’ parent/s or authorized legal guardian provided written informed consent for the collection and use of their data in this study.
